Cancer colorectal : les nouveaux rôles du pathologiste à l’ère de la biologie moléculaire et des thérapies « ciblées »
✍ Scribed by Magali Svrcek; Pascale Cervera; Richard Hamelin; Olivier Lascols; Alex Duval; Jean-François Fléjou
- Publisher
- Elsevier
- Year
- 2011
- Tongue
- French
- Weight
- 689 KB
- Volume
- 2011
- Category
- Article
- ISSN
- 1773-035X
No coin nor oath required. For personal study only.
✦ Synopsis
Colorectal cancer : news roles for the pathologists in the era of molecular biology and "targeted" therapies Colorectal cancer (CRC) is the second most common cause of cancer for both genders, with nearly 40 000 new diagnosed cases for a year in France in 2005. Recent advances in our understanding of colorectal carcinogenesis have given rise to the development of "targeted" therapies, in particular anti-EGFR antibodies, which are henceforth used in the treatment of metastasized CRCs. These "targeted" therapies, adapted to every patient and which base themselves on the genetic characteristics of the tumor, require the best possible selection of the patients. Actually, pathologists are spent for the management of CRCs from the era of the pTNM classification and classical pathological predictive factors to the era of the molecular biology and genetics. Indeed, they are directly involved in the determination of predictive markers of response to anti-EGFR therapies, with the investigation of KRAS mutation status. The pathologists are also involved in the determination of the MSI (microsatellite instability) status of tumors, a particular phenotype associated with inherited CRCs which it is important to detect, but which also seems to have a prognostic and therapeutic impact. All these techniques must be made in a quality assurance approach.
Cancer colorectal -thérapies ciblées -instabilité des microsatellites -KRAS
anticorps anti-EGFR -immunohistochimie. RÉSUMÉ L l t l (CCR) é t l d iè l l f é t Magali Svrcek a,b,c, *, Pascale Cervera a,b,d , Richard Hamelin b , Olivier Lascols c,d , Alex Duval b , Jean-François Fléjou a,b,c,e Cancer colorectal : les nouveaux rôles du pathologiste à l'ère de la biologie moléculaire et des thérapies « ciblées » * Lymphocytes infiltrant la tumeur (TIL), réaction lymphocytaire de type Crohn, cellules mucineuses en bague à chaton ou aspect médullaire. D'après Umar, 2004 [15].